H.pylori gastric adenocarcinoma pathophysiology: Difference between revisions
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
*Gastric cancer is the second leading cause of cancer-related deaths worldwide and H.pylori is the strongest known risk factor for gastric cancer.<ref name="pmid11556297">{{cite journal| author=Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M et al.| title=Helicobacter pylori infection and the development of gastric cancer. | journal=N Engl J Med | year= 2001 | volume= 345 | issue= 11 | pages= 784-9 | pmid=11556297 | doi=10.1056/NEJMoa001999 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11556297 }} </ref> | *Gastric cancer is the second leading cause of cancer-related deaths worldwide and H.pylori is the strongest known risk factor for gastric cancer.<ref name="pmid11556297">{{cite journal| author=Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M et al.| title=Helicobacter pylori infection and the development of gastric cancer. | journal=N Engl J Med | year= 2001 | volume= 345 | issue= 11 | pages= 784-9 | pmid=11556297 | doi=10.1056/NEJMoa001999 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11556297 }} </ref> | ||
*H.pylori is considered as Type I carcinogen. Among infected individuals, 1 to 3% develop gastric adenocarcinoma.<ref name="pmid11556297">{{cite journal| author=Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M et al.| title=Helicobacter pylori infection and the development of gastric cancer. | journal=N Engl J Med | year= 2001 | volume= 345 | issue= 11 | pages= 784-9 | pmid=11556297 | doi=10.1056/NEJMoa001999 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11556297 }} </ref> | *H.pylori is considered as Type I carcinogen. Among infected individuals, 1 to 3% develop gastric adenocarcinoma.<ref name="pmid11556297">{{cite journal| author=Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M et al.| title=Helicobacter pylori infection and the development of gastric cancer. | journal=N Engl J Med | year= 2001 | volume= 345 | issue= 11 | pages= 784-9 | pmid=11556297 | doi=10.1056/NEJMoa001999 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11556297 }} </ref> | ||
*Patients with H.pylori infection with severe atrophic gastritis, corpus predominant gastritis, or both and Intestinal metaplasia are at increased risk for intestinal-type gastric carcinoma.<ref name="pmid11556297">{{cite journal| author=Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M et al.| title=Helicobacter pylori infection and the development of gastric cancer. | journal=N Engl J Med | year= 2001 | volume= 345 | issue= 11 | pages= 784-9 | pmid=11556297 | doi=10.1056/NEJMoa001999 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11556297 }} </ref> | *Patients with H.pylori infection with severe atrophic gastritis, corpus predominant gastritis, or both and Intestinal metaplasia are at increased risk for intestinal-type gastric carcinoma.<ref name="pmid11556297">{{cite journal| author=Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M et al.| title=Helicobacter pylori infection and the development of gastric cancer. | journal=N Engl J Med | year= 2001 | volume= 345 | issue= 11 | pages= 784-9 | pmid=11556297 | doi=10.1056/NEJMoa001999 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11556297 }} </ref><ref name="pmid1458460">{{cite journal| author=Correa P| title=Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. | journal=Cancer Res | year= 1992 | volume= 52 | issue= 24 | pages= 6735-40 | pmid=1458460 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1458460 }} </ref> | ||
Revision as of 15:55, 13 January 2017
|
Helicobacter pylori infection Microchapters |
|
Differentiating Helicobacter pylori infection from other Diseases |
|---|
|
Diagnosis |
|
Guideline Recommendation |
|
Treatment |
|
Case Studies |
|
H.pylori gastric adenocarcinoma pathophysiology On the Web |
|
American Roentgen Ray Society Images of H.pylori gastric adenocarcinoma pathophysiology |
|
Directions to Hospitals Treating Helicobacter pylori infection |
|
Risk calculators and risk factors for H.pylori gastric adenocarcinoma pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yamuna Kondapally, M.B.B.S[2]
Overview
Pathophysiology
- Gastric cancer is the second leading cause of cancer-related deaths worldwide and H.pylori is the strongest known risk factor for gastric cancer.[1]
- H.pylori is considered as Type I carcinogen. Among infected individuals, 1 to 3% develop gastric adenocarcinoma.[1]
- Patients with H.pylori infection with severe atrophic gastritis, corpus predominant gastritis, or both and Intestinal metaplasia are at increased risk for intestinal-type gastric carcinoma.[1][2]
Pathogenesis
References
- ↑ 1.0 1.1 1.2 Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M; et al. (2001). "Helicobacter pylori infection and the development of gastric cancer". N Engl J Med. 345 (11): 784–9. doi:10.1056/NEJMoa001999. PMID 11556297.
- ↑ Correa P (1992). "Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention". Cancer Res. 52 (24): 6735–40. PMID 1458460.